With Jack Young our featured guest at the upcoming Mobile LAVA Healthcare event next week, we’ve been looking to see what Jack has been up to. Recently, Mobile Health News published a piece on a cellular enabled glucose monitor, Telcare, that raised $25.5 M from Sequoia and Qualcomm. This was a follow-on round for Telcare, a round that Qualcomm also lead.
Here is the article from MHN – Telcare raises $25.5 million from Sequoia, Qualcomm
And from the press release included in the article above:
“Telcare’s solution leverages the broad coverage of mobile networks and the convenience of cellular technology to empower individuals to better manage their conditions through professional supervision and/or family members’ support, said Jack Young, director of Qualcomm Ventures.
Telcare provides a comprehensive diabetes solution consisting of a wireless glucose meter with two-way messaging that transmits to an FDA-cleared care management server, along with a suite of iPhone and Android apps to enable family members to follow the progress of loved ones with diabetes. Through Sequoia’s investment, the company will seek to aggressively accelerate market share to realize their vision of becoming the global leader in wireless “mHealth” solutions for people with Diabetes and other chronic illnesses. The Telcare platform is currently being implemented by health insurers and employers who currently care for more than 1 million people with Diabetes.
Registration is required for the Mobile LAVA Healthcare event and is now open at: Mobile LAVA. The meeting’s format will be highly interactive. Following a few introductory minutes by the moderator, Richard Koffler, the floor will open to questions from the audience. The event will be held at tiato, 6:30 PM on September 27. Free parking is available under the building at 2700 Colorado, 90404 after 5:00 PM with validation.
Mobile LAVA and LAVA Healthcare are Strategic Interest Groups of the Los Angeles Venture Association.
Mobile LAVA events and SIG are generously supported by Gumiyo and Ernst & Young.